FI973437A - Soluimmuniteetin uudelleenkohdistus reseptorikimeerien avulla - Google Patents

Soluimmuniteetin uudelleenkohdistus reseptorikimeerien avulla Download PDF

Info

Publication number: FI973437A
Authority: FI; Finland
Prior art keywords: cell; infective agent; chimeric receptors; target; receptor
Prior art date: 1995-02-24

Application number

FI973437A

Other languages

English (en)

Swedish (sv)

Other versions

FI119757B (fi

FI973437A0 (fi

Inventor

Brian Seed

Charles Romeo

Waldemar Kolanus

Original Assignee

Gen Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-24

Filing date

1997-08-21

Publication date

1997-10-16

1997-08-21 Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp

1997-08-21 Publication of FI973437A0 publication Critical patent/FI973437A0/fi

1997-10-16 Publication of FI973437A publication Critical patent/FI973437A/fi

2009-03-13 Application granted granted Critical

2009-03-13 Publication of FI119757B publication Critical patent/FI119757B/fi

Links

230000007969 cellular immunity Effects 0.000 title 1
108700010039 chimeric receptor Proteins 0.000 abstract 6
230000001524 infective effect Effects 0.000 abstract 5
241000124008 Mammalia Species 0.000 abstract 2
230000003834 intracellular effect Effects 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
230000036755 cellular response Effects 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000011664 signaling Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FI973437A 1995-02-24 1997-08-21 Solut, jotka ilmentävät kimeeristen reseptorien yhdistelmää, ja niiden käyttö terapiassa FI119757B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US39417695A	1995-02-24	1995-02-24
US39417695		1995-02-24
US9601056		1996-01-25
PCT/US1996/001056 WO1996025953A1 (en)	1995-02-24	1996-01-25	Redirection of cellular immunity by receptor chimeras

Publications (3)

Publication Number	Publication Date
FI973437A0 FI973437A0 (fi)	1997-08-21
FI973437A true FI973437A (fi)	1997-10-16
FI119757B FI119757B (fi)	2009-03-13

Family

ID=23557882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI973437A FI119757B (fi)	1995-02-24	1997-08-21	Solut, jotka ilmentävät kimeeristen reseptorien yhdistelmää, ja niiden käyttö terapiassa

Country Status (18)

Country	Link
EP (1)	EP0871495B1 (fi)
JP (1)	JP4170390B2 (fi)
KR (1)	KR100490099B1 (fi)
AT (1)	ATE297986T1 (fi)
AU (1)	AU708339B2 (fi)
CA (1)	CA2209300C (fi)
CZ (1)	CZ295428B6 (fi)
DE (1)	DE69634855T2 (fi)
DK (1)	DK0871495T3 (fi)
ES (1)	ES2245456T3 (fi)
FI (1)	FI119757B (fi)
HU (1)	HU225688B1 (fi)
NO (1)	NO323632B1 (fi)
NZ (2)	NZ337002A (fi)
PT (1)	PT871495E (fi)
RU (1)	RU2167676C2 (fi)
WO (1)	WO1996025953A1 (fi)
ZA (1)	ZA961477B (fi)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU733719B2 (en) *	1996-10-23	2001-05-24	Trustees Of The University Of Pennsylvania, The	Improved vaccines
AU6692298A (en) *	1997-03-07	1998-09-22	Ariad Gene Therapeutics, Inc.	New applications of gene therapy technology
EP2105446B1 (en) *	1998-09-23	2013-08-14	ZymoGenetics, Inc.	Cytokine receptor zalpha11
GB9908807D0 (en) *	1999-04-16	1999-06-09	Celltech Therapeutics Ltd	Synthetic signalling molecules
IL137419A0 (en) *	2000-07-20	2001-07-24	Yissum Res Dev Co	Nk cells activating receptors and their therapeutic and diagnostic uses
WO2006036445A2 (en)	2004-09-24	2006-04-06	Trustees Of Dartmouth College	Chimeric nk receptor and methods for treating cancer
US9273283B2 (en)	2009-10-29	2016-03-01	The Trustees Of Dartmouth College	Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en)	2009-10-29	2011-05-19	Trustees Of Dartmouth College	T cell receptor-deficient t cell compositions
BR122021026169B1 (pt)	2010-12-09	2023-12-12	The Trustees Of The University Of Pennsylvania	Uso de uma célula
WO2013033626A2 (en)	2011-08-31	2013-03-07	Trustees Of Dartmouth College	Nkp30 receptor targeted therapeutics
GB201201511D0 (en) *	2012-01-30	2012-03-14	Univ Leuven Kath	Modified epitopes for boosting CD4+ T-cell responses
CN110511278A (zh)	2012-05-07	2019-11-29	达特茅斯大学理事会	抗b7-h6抗体、融合蛋白及其使用方法
KR20150029714A (ko)	2012-07-13	2015-03-18	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
WO2014055657A1 (en)	2012-10-05	2014-04-10	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
WO2014130635A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
RU2708032C2 (ru)	2013-02-20	2019-12-03	Новартис Аг	ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
EP2970426B1 (en)	2013-03-15	2019-08-28	Michael C. Milone	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es)	2013-03-16	2014-10-31	Novartis Ag	Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CA3225453A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en)	2013-12-20	2024-06-05	Novartis AG	Regulatable chimeric antigen receptor
CA2933707A1 (en) *	2013-12-20	2015-06-25	Fred Hutchinson Cancer Research Center	Tagged chimeric effector molecules and receptors thereof
WO2015112626A1 (en)	2014-01-21	2015-07-30	June Carl H	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
HUE054588T2 (hu)	2014-04-07	2021-09-28	Novartis Ag	Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
MY181834A (en)	2014-07-21	2021-01-08	Novartis Ag	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
CA2955154C (en)	2014-07-21	2023-10-31	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
AR101829A1 (es)	2014-07-21	2017-01-18	Novartis Ag	Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
PL3183268T3 (pl)	2014-08-19	2020-09-07	Novartis Ag	Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
WO2016044605A1 (en)	2014-09-17	2016-03-24	Beatty, Gregory	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
IL308324A (en) *	2014-09-19	2024-01-01	Hope City	IL13RA2-targeted chimeric antigen receptor T cells
KR20170068504A (ko)	2014-10-08	2017-06-19	노파르티스 아게	키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
IL253149B2 (en)	2014-12-29	2023-11-01	Novartis Ag	Methods for preparing cells expressing a chimeric receptor antigen
WO2016115482A1 (en)	2015-01-16	2016-07-21	Novartis Pharma Ag	Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
EP4056588A1 (en)	2015-04-08	2022-09-14	Novartis AG	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
CA2982996A1 (en)	2015-04-17	2016-10-20	David Maxwell Barrett	Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2017004252A1 (en)	2015-06-30	2017-01-05	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
AU2016297014B2 (en)	2015-07-21	2021-06-17	Novartis Ag	Methods for improving the efficacy and expansion of immune cells
GB201513540D0 (en) *	2015-07-31	2015-09-16	King S College London	Therapeutic agents
WO2017027392A1 (en)	2015-08-07	2017-02-16	Novartis Ag	Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (zh)	2015-09-03	2022-07-22	诺华股份有限公司	预测细胞因子释放综合征的生物标志物
JP7082055B2 (ja)	2015-12-22	2022-06-07	ノバルティスアーゲー	抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
CN117866991A (zh)	2016-10-07	2024-04-12	诺华股份有限公司	用于治疗癌症的嵌合抗原受体
EP4043485A1 (en)	2017-01-26	2022-08-17	Novartis AG	Cd28 compositions and methods for chimeric antigen receptor therapy
RU2019133280A (ru)	2017-03-22	2021-04-22	Новартис Аг	Композиции и способы для иммуноонкологии
KR20200086278A (ko)	2017-10-18	2020-07-16	노파르티스 아게	선택적 단백질 분해를 위한 조성물 및 방법
JP2021514658A (ja)	2018-03-06	2021-06-17	ザトラスティーズオブザユニバーシティオブペンシルバニア	前立腺特異的膜抗原ｃａｒおよびその使用方法
AU2019284911A1 (en)	2018-06-13	2020-12-17	Novartis Ag	BCMA chimeric antigen receptors and uses thereof
CN114945382A (zh)	2019-11-26	2022-08-26	诺华股份有限公司	Cd19和cd22嵌合抗原受体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69123241T2 (de) *	1990-12-14	1997-04-17	Cell Genesys Inc	Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
IL101147A (en) *	1991-03-07	2004-06-20	Gen Hospital Corp	Change of direction of cellular immunity by chimera receptors
US5912170A (en) *	1991-03-07	1999-06-15	The General Hospital Corporation	Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5439819A (en) *	1993-08-27	1995-08-08	The Regents Of The University Of California	Chimeric protein tyrosine kinases

1996
- 1996-01-25 DE DE69634855T patent/DE69634855T2/de not_active Expired - Lifetime
- 1996-01-25 JP JP52568596A patent/JP4170390B2/ja not_active Expired - Lifetime
- 1996-01-25 AT AT96904498T patent/ATE297986T1/de active
- 1996-01-25 NZ NZ337002A patent/NZ337002A/en not_active IP Right Cessation
- 1996-01-25 WO PCT/US1996/001056 patent/WO1996025953A1/en active IP Right Grant
- 1996-01-25 EP EP96904498A patent/EP0871495B1/en not_active Expired - Lifetime
- 1996-01-25 AU AU48588/96A patent/AU708339B2/en not_active Expired
- 1996-01-25 KR KR1019970705850A patent/KR100490099B1/ko not_active IP Right Cessation
- 1996-01-25 CA CA2209300A patent/CA2209300C/en not_active Expired - Lifetime
- 1996-01-25 NZ NZ302513A patent/NZ302513A/xx not_active IP Right Cessation
- 1996-01-25 RU RU97115769/14A patent/RU2167676C2/ru active
- 1996-01-25 PT PT96904498T patent/PT871495E/pt unknown
- 1996-01-25 HU HU9801873A patent/HU225688B1/hu unknown
- 1996-01-25 ES ES96904498T patent/ES2245456T3/es not_active Expired - Lifetime
- 1996-01-25 CZ CZ19972599A patent/CZ295428B6/cs not_active IP Right Cessation
- 1996-01-25 DK DK96904498T patent/DK0871495T3/da active
- 1996-02-23 ZA ZA9601477A patent/ZA961477B/xx unknown
1997
- 1997-08-21 FI FI973437A patent/FI119757B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973864A patent/NO323632B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP9801873A2 (hu)	1998-11-30
NO973864L (no)	1997-10-22
ES2245456T3 (es)	2006-01-01
NO323632B1 (no)	2007-06-18
FI119757B (fi)	2009-03-13
KR100490099B1 (ko)	2005-11-28
KR19980702450A (ko)	1998-07-15
CZ259997A3 (cs)	1998-05-13
HU225688B1 (en)	2007-06-28
PT871495E (pt)	2005-10-31
EP0871495B1 (en)	2005-06-15
CZ295428B6 (cs)	2005-08-17
DE69634855T2 (de)	2006-05-18
CA2209300A1 (en)	1996-08-29
NZ337002A (en)	2005-07-29
WO1996025953A1 (en)	1996-08-29
JP4170390B2 (ja)	2008-10-22
ATE297986T1 (de)	2005-07-15
FI973437A0 (fi)	1997-08-21
CA2209300C (en)	2011-06-28
AU708339B2 (en)	1999-08-05
DK0871495T3 (da)	2005-10-17
RU2167676C2 (ru)	2001-05-27
NZ302513A (en)	1999-11-29
EP0871495A4 (en)	2000-09-13
NO973864D0 (no)	1997-08-22
AU4858896A (en)	1996-09-11
HUP9801873A3 (en)	2000-08-28
EP0871495A1 (en)	1998-10-21
JPH11505409A (ja)	1999-05-21
DE69634855D1 (de)	2005-07-21
ZA961477B (en)	1997-02-03

Legal Events

Date

Code

Title

Description

2009-03-13

FG

Patent granted

Ref document number: 119757

Country of ref document: FI

2016-02-29

MA

Patent expired

Publication	Publication Date	Title
FI973437A0 (fi)	1997-08-21	Soluimmuniteetin uudelleenkohdistus reseptorikimeerien avulla
FI973466A (fi)	1997-08-22	Soluimmuniteetin suuntaaminen uudelleen proteiinityrosiinikinaasikimeerojen avulla
ATE308888T1 (de)	2005-11-15	Gezielte zell-lyse von hiv-infizierten zellen mit chimären cd4 rezeptortragenden zellen
AU3032895A (en)	1996-01-11	Redirection of cellular immunity by receptor chimeras
NO960175D0 (no)	1996-01-15	Redirigering av cellulær immunitet med reseptor-chimeras